Health news today spans both high-stakes drug competition and the quieter gaps in everyday care. Novo Nordisk has taken Eli Lilly to federal court, accusing its rival of misleading advertising in the fierce battle over blockbuster GLP-1 treatments, arguing Lilly’s promotions for Zepbound and Mounjaro rely on selective, outdated comparisons that overstate their edge over Wegovy and Ozempic. At the consumer end of health tech, Garmin is pushing into the screen-free wearable market with its new Cirqa smart band, betting that distraction-free tracking without a subscription will appeal to users weary of recurring fees. And in a reminder that innovation does not erase basic shortcomings in care, Melinda French Gates says it took three doctors to diagnose her perimenopause, underscoring persistent blind spots in women’s health even for patients with excellent access to medicine.